Amanda is a 56-year-old female who has rheumatoid arthritis (RA) with morning joint pain, stiffness, and swelling in the hands

Despite treatment with a DMARD, she still experienced morning flare-ups of symptoms that disrupted her work schedule and daily activities

Amanda was interested in exploring an additional treatment that may reduce the duration and severity of morning stiffness

As an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation

For the treatment of certain endocrine conditions

For palliation of certain neoplastic conditions

Learn how RAYOS can be taken at bedtime to achieve peak plasma concentrations that match the peak in proinflammatory cytokine cycles^1-3

Explore clinical trial data showing how adding RAYOS to stable DMARD therapy can significantly improve clinical response and shorten the duration of RA symptoms, including morning stiffness^1,3

Discover how the multiple dosing strengths of RAYOS enable small titration increments to reach the lowest dose that will maintain an effective clinical response³

Known hypersensitivity to prednisone or any excipients in the formulation

Corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and hyperglycemia. Monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use

RAYOS may increase susceptibility to new infection and increase risk of exacerbation, dissemination or reactivation of latent infection. RAYOS may mask signs and symptoms of infection. The rate of infectious complications increases with increasing doses of corticosteroids

Corticosteroids can cause elevated blood pressure, salt and water retention and hypokalemia. Monitor blood pressure and sodium, potassium serum levels. RAYOS should be used with caution in patients with a history of recent myocardial infarction, congestive heart failure, hypertension or renal insufficiency

There is an increased risk of gastrointestinal (GI) perforation in patients with certain GI disorders. RAYOS may mask signs and symptoms of GI perforation

Corticosteroid use may be associated with behavioral and mood disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression and psychosis. Existing conditions may be aggravated

Corticosteroid use may lead to inhibition of bone growth in children and adolescents and the development of osteoporosis at any age. Give special consideration to patients at increased risk of osteoporosis (eg, postmenopausal women) before initiating corticosteroid therapy, and bone density should be monitored in patients on long-term corticosteroid therapy

Prolonged use of corticosteroids may result in cataracts, infections and glaucoma. Monitor intraocular pressure if corticosteroid therapy is continued for more than 6 weeks

Do not administer live or attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids

Long‐term use of corticosteroids can have negative effects on growth and development in children. Monitor pediatric patients on long‐term corticosteroid therapy

Corticosteroids can cause fetal harm, including a small but inconsistent risk of orofacial clefts during the first trimester. Advise pregnant women of potential harm to the fetus

Prednisolone has been found in human milk following administration to lactating women; use the lowest dose in lactating women to achieve desired clinical effect

1.

Buttgereit F, Mehta D, Kirwan J, et al. Low dose prednisone chronotherapy for rheumatoid arthritis: a randomized clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72(2):204-210.

2.

Cutolo M, Masi AT. Circadian rhythms and arthritis. Rheum Dis Clin North Am. 2005;31(1):115-129.

3.

RAYOS (prednisone) delayed-release tablets [prescribing information]. Horizon.

4.

2021 HorizonCares Pharmacy Sourced Data + PSKW. Horizon.